r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

EB

Eric Benevich

Insider · Chief Commercial Officer · NBIX

Eric Benevich files insider transactions with the SEC as a chief commercial officer of Neurocrine Biosciences. We hold 1 disclosed purchase or sale filed since 3 June 2015, 1 of them in the last 90 days.

  • Files for 2 companiesNBIX, ATYR
  • Disclosed buys and sells1 in all, 1 in the last 90 days
  • Last disclosure10 September 2026

Positions held

2 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 1 June 2015 — 9 September 2026Chief Commercial Officer · Neurocrine Biosciences 169 Form 4 lines · source: SEC Form 4
  • Filed 10 December 2024 — 11 May 2026Director · aTYR PHARMA 3 Form 4 lines · source: SEC Form 4

Every transaction

172 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
172 of 172 shown
9 Sep 202610 Sep 2026SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciences3,194 sharesup +0.7%down −0.2%
9 Sep 202610 Sep 2026SEC Form 41 dsold on the open marketNeurocrine Biosciences2,154 sharesup +0.7%down −0.2%
9 Sep 202610 Sep 2026SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciencesderivative3,194 sharesup +0.7%down −0.2%
11 May 202613 May 2026SEC Form 42 dwas grantednot a tradeaTYR PHARMAderivative50,000 sharesdown −54.8%up +8.5%
13 Feb 202617 Feb 2026SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciencesderivative1,961 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciencesderivative2,083 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dwas grantednot a tradeNeurocrine Biosciencesderivative36,287 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dwas grantednot a tradeNeurocrine Biosciencesderivative6,365 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciences1,961 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciencesderivative1,961 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciencesderivative2,083 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dwas grantednot a tradeNeurocrine Biosciencesderivative36,287 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dwas grantednot a tradeNeurocrine Biosciencesderivative6,365 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dhad shares withheld for taxnot a tradeNeurocrine Biosciences1,058 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciences2,083 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dhad shares withheld for taxnot a tradeNeurocrine Biosciences1,124 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dwas grantednot a tradeNeurocrine Biosciences16,613 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dhad shares withheld for taxnot a tradeNeurocrine Biosciences8,963 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciences1,961 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dhad shares withheld for taxnot a tradeNeurocrine Biosciences1,058 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciences2,083 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dhad shares withheld for taxnot a tradeNeurocrine Biosciences1,124 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dwas grantednot a tradeNeurocrine Biosciences16,613 sharesup +25.9%up +22.3%
13 Feb 202617 Feb 2026SEC Form 44 dhad shares withheld for taxnot a tradeNeurocrine Biosciences8,963 sharesup +25.9%up +22.3%
12 Feb 202617 Feb 2026SEC Form 45 dexercised options overnot a tradeNeurocrine Biosciences2,005 sharesup +26.9%up +22.3%
12 Feb 202617 Feb 2026SEC Form 45 dhad shares withheld for taxnot a tradeNeurocrine Biosciences1,082 sharesup +26.9%up +22.3%
12 Feb 202617 Feb 2026SEC Form 45 dexercised options overnot a tradeNeurocrine Biosciencesderivative2,005 sharesup +26.9%up +22.3%
12 Feb 202617 Feb 2026SEC Form 45 dexercised options overnot a tradeNeurocrine Biosciences2,005 sharesup +26.9%up +22.3%
12 Feb 202617 Feb 2026SEC Form 45 dhad shares withheld for taxnot a tradeNeurocrine Biosciences1,082 sharesup +26.9%up +22.3%
12 Feb 202617 Feb 2026SEC Form 45 dexercised options overnot a tradeNeurocrine Biosciencesderivative2,005 sharesup +26.9%up +22.3%
31 Jan 20263 Feb 2026SEC Form 43 dexercised options overnot a tradeNeurocrine Biosciences2,294 sharesup +14.8%up +12.4%
31 Jan 20263 Feb 2026SEC Form 43 dhad shares withheld for taxnot a tradeNeurocrine Biosciences1,292 sharesup +14.8%up +12.4%
31 Jan 20263 Feb 2026SEC Form 43 dexercised options overnot a tradeNeurocrine Biosciencesderivative2,294 sharesup +14.8%up +12.4%
31 Jan 20263 Feb 2026SEC Form 43 dexercised options overnot a tradeNeurocrine Biosciencesderivative2,294 sharesup +14.8%up +12.4%
31 Jan 20263 Feb 2026SEC Form 43 dexercised options overnot a tradeNeurocrine Biosciences2,294 sharesup +14.8%up +12.4%
31 Jan 20263 Feb 2026SEC Form 43 dhad shares withheld for taxnot a tradeNeurocrine Biosciences1,292 sharesup +14.8%up +12.4%
28 Nov 202516 Jan 2026SEC Form 449 dexercised options overnot a tradeNeurocrine Biosciences12,830 sharesup +2.7%up +18.0%
28 Nov 202516 Jan 2026SEC Form 449 dexercised options overnot a tradeNeurocrine Biosciencesderivative12,830 sharesup +2.7%up +18.0%
28 Nov 202516 Jan 2026SEC Form 449 dexercised options overnot a tradeNeurocrine Biosciencesderivative12,830 sharesup +2.7%up +18.0%
28 Nov 202516 Jan 2026SEC Form 449 dexercised options overnot a tradeNeurocrine Biosciences12,830 sharesup +2.7%up +18.0%
28 Nov 20252 Dec 2025SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciencesderivative5,970 sharesup +2.7%up +2.5%
28 Nov 20252 Dec 2025SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciences5,970 sharesup +2.7%up +2.5%
28 Nov 20252 Dec 2025SEC Form 44 dsold on the open marketNeurocrine Biosciences5,970 sharesup +2.7%up +2.5%
1 May 20252 May 2025SEC Form 41 dwas grantednot a tradeaTYR PHARMAderivative50,000 sharesdown −87.1%down −88.1%
13 Feb 202514 Feb 2025SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciencesderivative2,083 sharesup +33.7%up +35.8%
13 Feb 202514 Feb 2025SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciencesderivative1,961 sharesup +33.7%up +35.8%
13 Feb 202514 Feb 2025SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciences2,083 sharesup +33.7%up +35.8%
13 Feb 202514 Feb 2025SEC Form 41 dsold on the open marketNeurocrine Biosciences1,098 sharesup +33.7%up +35.8%
13 Feb 202514 Feb 2025SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciences1,961 sharesup +33.7%up +35.8%
13 Feb 202514 Feb 2025SEC Form 41 dsold on the open marketNeurocrine Biosciences1,056 sharesup +33.7%up +35.8%
12 Feb 202514 Feb 2025SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative42,805 sharesup +33.3%up +35.8%
12 Feb 202514 Feb 2025SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative8,022 sharesup +33.3%up +35.8%
10 Feb 202512 Feb 2025SEC Form 42 dsold on the open marketNeurocrine Biosciences980 sharesup +31.5%up +33.3%
8 Feb 202512 Feb 2025SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciencesderivative1,860 sharesup +27.4%up +33.3%
8 Feb 202512 Feb 2025SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciences1,860 sharesup +27.4%up +33.3%
31 Jan 20254 Feb 2025SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciencesderivative2,294 sharesup +2.9%up +2.5%
31 Jan 20254 Feb 2025SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciences2,294 sharesup +2.9%up +2.5%
31 Jan 20254 Feb 2025SEC Form 44 dsold on the open marketNeurocrine Biosciences1,207 sharesup +2.9%up +2.5%
10 Dec 202412 Dec 2024SEC Form 42 dwas grantednot a tradeaTYR PHARMAderivative100,000 sharesdown −86.9%down −85.8%
15 Apr 202417 Apr 2024SEC Form 42 dexercised options overnot a tradeNeurocrine Biosciencesderivative7,231 sharesup +18.6%up +17.3%
15 Apr 202417 Apr 2024SEC Form 42 dexercised options overnot a tradeNeurocrine Biosciencesderivative12,587 sharesup +18.6%up +17.3%
15 Apr 202417 Apr 2024SEC Form 42 dexercised options overnot a tradeNeurocrine Biosciences7,231 sharesup +18.6%up +17.3%
15 Apr 202417 Apr 2024SEC Form 42 dsold on the open marketNeurocrine Biosciences7,231 sharesup +18.6%up +17.3%
15 Apr 202417 Apr 2024SEC Form 42 dexercised options overnot a tradeNeurocrine Biosciences12,587 sharesup +18.6%up +17.3%
15 Apr 202417 Apr 2024SEC Form 42 dsold on the open marketNeurocrine Biosciences12,587 sharesup +18.6%up +17.3%
14 Mar 202415 Mar 2024SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciencesderivative5,479 sharesup +12.3%up +12.3%
14 Mar 202415 Mar 2024SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciencesderivative69,521 sharesup +12.3%up +12.3%
14 Mar 202415 Mar 2024SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciences5,479 sharesup +12.3%up +12.3%
14 Mar 202415 Mar 2024SEC Form 41 dsold on the open marketNeurocrine Biosciences5,479 sharesup +12.3%up +12.3%
14 Mar 202415 Mar 2024SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciences69,521 sharesup +12.3%up +12.3%
14 Mar 202415 Mar 2024SEC Form 41 dsold on the open marketNeurocrine Biosciences69,521 sharesup +12.3%up +12.3%
28 Feb 202429 Feb 2024SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciencesderivative53,143 sharesup +16.0%up +19.8%
28 Feb 202429 Feb 2024SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciencesderivative21,857 sharesup +16.0%up +19.8%
28 Feb 202429 Feb 2024SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciences53,143 sharesup +16.0%up +19.8%
28 Feb 202429 Feb 2024SEC Form 41 dsold on the open marketNeurocrine Biosciences53,143 sharesup +16.0%up +19.8%
28 Feb 202429 Feb 2024SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciences21,857 sharesup +16.0%up +19.8%
28 Feb 202429 Feb 2024SEC Form 41 dsold on the open marketNeurocrine Biosciences21,857 sharesup +16.0%up +19.8%
13 Feb 202415 Feb 2024SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative39,426 sharesup +16.7%up +16.6%
13 Feb 202415 Feb 2024SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative7,846 sharesup +16.7%up +16.6%
13 Feb 202415 Feb 2024SEC Form 42 dsold on the open marketNeurocrine Biosciences1,098 sharesup +16.7%up +16.6%
8 Feb 20248 Feb 2024SEC Form 40 dsold on the open marketNeurocrine Biosciences980 sharesup +16.2%up +16.2%
6 Feb 20248 Feb 2024SEC Form 42 dsold on the open marketNeurocrine Biosciences1,280 sharesup +9.3%up +16.2%
31 Jan 20242 Feb 2024SEC Form 42 dsold on the open marketNeurocrine Biosciences1,207 sharesup +11.8%up +10.2%
21 Aug 202323 Aug 2023SEC Form 42 dsold on the open marketNeurocrine Biosciences1,600 sharesup +44.2%up +45.1%
13 Feb 202315 Feb 2023SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative51,782 sharesup +50.9%up +50.6%
13 Feb 202315 Feb 2023SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative8,332 sharesup +50.9%up +50.6%
8 Feb 20238 Feb 2023SEC Form 40 dsold on the open marketNeurocrine Biosciences980 sharesup +49.5%up +49.5%
7 Feb 20238 Feb 2023SEC Form 41 dsold on the open marketNeurocrine Biosciences2,030 sharesup +50.5%up +49.5%
7 Feb 20238 Feb 2023SEC Form 41 dsold on the open marketNeurocrine Biosciences15,360 sharesup +50.5%up +49.5%
6 Feb 20238 Feb 2023SEC Form 42 dsold on the open marketNeurocrine Biosciences1,280 sharesup +48.8%up +49.5%
31 Jan 20232 Feb 2023SEC Form 42 dsold on the open marketNeurocrine Biosciences1,207 sharesup +40.8%up +44.6%
6 Jan 202310 Jan 2023SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciencesderivative400 sharesup +27.0%up +42.3%
6 Jan 202310 Jan 2023SEC Form 44 dexercised options overnot a tradeNeurocrine Biosciences400 sharesup +27.0%up +42.3%
6 Jan 202310 Jan 2023SEC Form 44 dsold on the open marketNeurocrine Biosciences400 sharesup +27.0%up +42.3%
30 Nov 20221 Dec 2022SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciencesderivative22,162 sharesup +22.9%up +23.7%
30 Nov 20221 Dec 2022SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciencesderivative7,775 sharesup +22.9%up +23.7%
30 Nov 20221 Dec 2022SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciencesderivative20,063 sharesup +22.9%up +23.7%
30 Nov 20221 Dec 2022SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciences22,162 sharesup +22.9%up +23.7%
30 Nov 20221 Dec 2022SEC Form 41 dsold on the open marketNeurocrine Biosciences22,162 sharesup +22.9%up +23.7%
30 Nov 20221 Dec 2022SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciences7,775 sharesup +22.9%up +23.7%
30 Nov 20221 Dec 2022SEC Form 41 dsold on the open marketNeurocrine Biosciences7,775 sharesup +22.9%up +23.7%
30 Nov 20221 Dec 2022SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciences20,063 sharesup +22.9%up +23.7%
30 Nov 20221 Dec 2022SEC Form 41 dsold on the open marketNeurocrine Biosciences20,063 sharesup +22.9%up +23.7%
10 Nov 202210 Nov 2022SEC Form 40 dexercised options overnot a tradeNeurocrine Biosciencesderivative100 sharesup +26.8%up +26.8%
10 Nov 202210 Nov 2022SEC Form 40 dexercised options overnot a tradeNeurocrine Biosciences100 sharesup +26.8%up +26.8%
10 Nov 202210 Nov 2022SEC Form 40 dsold on the open marketNeurocrine Biosciences100 sharesup +26.8%up +26.8%
8 Nov 202210 Nov 2022SEC Form 42 dexercised options overnot a tradeNeurocrine Biosciencesderivative24,593 sharesup +26.1%up +26.8%
8 Nov 202210 Nov 2022SEC Form 42 dexercised options overnot a tradeNeurocrine Biosciences24,593 sharesup +26.1%up +26.8%
8 Nov 202210 Nov 2022SEC Form 42 dsold on the open marketNeurocrine Biosciences24,593 sharesup +26.1%up +26.8%
3 Nov 20224 Nov 2022SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciencesderivative8,968 sharesup +25.9%up +28.2%
3 Nov 20224 Nov 2022SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciences8,968 sharesup +25.9%up +28.2%
3 Nov 20224 Nov 2022SEC Form 41 dsold on the open marketNeurocrine Biosciences8,968 sharesup +25.9%up +28.2%
2 Nov 20224 Nov 2022SEC Form 42 dexercised options overnot a tradeNeurocrine Biosciencesderivative400 sharesup +28.0%up +28.2%
2 Nov 20224 Nov 2022SEC Form 42 dexercised options overnot a tradeNeurocrine Biosciences400 sharesup +28.0%up +28.2%
2 Nov 20224 Nov 2022SEC Form 42 dsold on the open marketNeurocrine Biosciences400 sharesup +28.0%up +28.2%
17 Oct 202219 Oct 2022SEC Form 42 dsold on the open marketNeurocrine Biosciences4,960 sharesup +40.7%up +42.7%
8 Feb 20229 Feb 2022SEC Form 41 dsold on the open marketNeurocrine Biosciences980 sharesup +95.5%up +92.6%
7 Feb 20229 Feb 2022SEC Form 42 dsold on the open marketNeurocrine Biosciences809 sharesup +92.8%up +92.6%
7 Feb 20229 Feb 2022SEC Form 42 dsold on the open marketNeurocrine Biosciences2,030 sharesup +92.8%up +92.6%
7 Feb 20229 Feb 2022SEC Form 42 dsold on the open marketNeurocrine Biosciences1,280 sharesup +92.8%up +92.6%
31 Jan 20222 Feb 2022SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative62,483 sharesup +97.7%up +98.4%
31 Jan 20222 Feb 2022SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative9,175 sharesup +97.7%up +98.4%
16 Aug 202118 Aug 2021SEC Form 42 dsold on the open marketNeurocrine Biosciences5,628 sharesup +73.2%up +70.2%
8 Feb 202126 Mar 2021SEC Form 446 dwas grantednot a tradeNeurocrine Biosciencesderivative49,049 sharesup +32.8%up +58.0%
8 Feb 20219 Feb 2021SEC Form 41 dwas grantednot a tradeNeurocrine Biosciencesderivative44,632 sharesup +32.8%up +35.1%
8 Feb 20219 Feb 2021SEC Form 41 dwas grantednot a tradeNeurocrine Biosciencesderivative7,439 sharesup +32.8%up +35.1%
8 Feb 20219 Feb 2021SEC Form 41 dsold on the open marketNeurocrine Biosciences845 sharesup +32.8%up +35.1%
8 Feb 20219 Feb 2021SEC Form 41 dsold on the open marketNeurocrine Biosciences1,395 sharesup +32.8%up +35.1%
8 Feb 20219 Feb 2021SEC Form 41 dsold on the open marketNeurocrine Biosciences2,030 sharesup +32.8%up +35.1%
5 Feb 20219 Feb 2021SEC Form 44 dsold on the open marketNeurocrine Biosciences809 sharesup +34.5%up +35.1%
26 Jan 202127 Jan 2021SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciencesderivative300 sharesup +34.5%up +41.0%
26 Jan 202127 Jan 2021SEC Form 41 dexercised options overnot a tradeNeurocrine Biosciences300 sharesup +34.5%up +41.0%
26 Jan 202127 Jan 2021SEC Form 41 dsold on the open marketNeurocrine Biosciences300 sharesup +34.5%up +41.0%
26 Jan 202127 Jan 2021SEC Form 41 dsold on the open marketNeurocrine Biosciences100 sharesup +34.5%up +41.0%
25 Jan 202127 Jan 2021SEC Form 42 dexercised options overnot a tradeNeurocrine Biosciencesderivative3,477 sharesup +30.8%up +41.0%
25 Jan 202127 Jan 2021SEC Form 42 dexercised options overnot a tradeNeurocrine Biosciences3,477 sharesup +30.8%up +41.0%
25 Jan 202127 Jan 2021SEC Form 42 dsold on the open marketNeurocrine Biosciences3,477 sharesup +30.8%up +41.0%
25 Jan 202127 Jan 2021SEC Form 42 dsold on the open marketNeurocrine Biosciences1,600 sharesup +30.8%up +41.0%
12 Nov 202016 Nov 2020SEC Form 44 dsold on the open marketNeurocrine Biosciences2,257 sharesup +72.7%up +68.1%
2 Nov 20204 Nov 2020SEC Form 42 dexercised options overnot a tradeNeurocrine Biosciencesderivative20,595 sharesup +62.8%up +44.2%
2 Nov 20204 Nov 2020SEC Form 42 dexercised options overnot a tradeNeurocrine Biosciences20,595 sharesup +62.8%up +44.2%
2 Nov 20204 Nov 2020SEC Form 42 dsold on the open marketNeurocrine Biosciences20,595 sharesup +62.8%up +44.2%
5 Aug 20207 Aug 2020SEC Form 42 dsold on the open marketNeurocrine Biosciences2,257 sharesup +31.4%up +35.7%
24 Apr 202028 Apr 2020SEC Form 44 dsold on the open marketNeurocrine Biosciences1,934 sharesup +59.1%up +58.4%
15 Apr 202017 Apr 2020SEC Form 42 dsold on the open marketNeurocrine Biosciences8,632 sharesup +64.2%up +57.9%
7 Feb 202011 Feb 2020SEC Form 44 dsold on the open marketNeurocrine Biosciences2,030 sharesup +50.2%up +46.0%
6 Feb 20207 Feb 2020SEC Form 41 dwas grantednot a tradeNeurocrine Biosciencesderivative61,347 sharesup +51.8%up +50.2%
6 Feb 20207 Feb 2020SEC Form 41 dwas grantednot a tradeNeurocrine Biosciencesderivative9,719 sharesup +51.8%up +50.2%
6 Feb 20207 Feb 2020SEC Form 41 dsold on the open marketNeurocrine Biosciences1,395 sharesup +51.8%up +50.2%
5 Feb 20207 Feb 2020SEC Form 42 dsold on the open marketNeurocrine Biosciences1,145 sharesup +52.5%up +50.2%
5 Feb 20207 Feb 2020SEC Form 42 dsold on the open marketNeurocrine Biosciences809 sharesup +52.5%up +50.2%
15 Jul 201917 Jul 2019SEC Form 42 dsold on the open marketNeurocrine Biosciences5,835 sharesup +78.4%up +77.3%
7 Feb 20198 Feb 2019SEC Form 41 dwas grantednot a tradeNeurocrine Biosciencesderivative83,341 sharesup +92.7%up +85.1%
7 Feb 20198 Feb 2019SEC Form 41 dwas grantednot a tradeNeurocrine Biosciencesderivative15,423 sharesup +92.7%up +85.1%
6 Feb 20198 Feb 2019SEC Form 42 dsold on the open marketNeurocrine Biosciences920 sharesup +85.1%up +85.1%
5 Feb 20196 Feb 2019SEC Form 41 dsold on the open marketNeurocrine Biosciences602 sharesup +78.0%up +85.1%
5 Feb 20196 Feb 2019SEC Form 41 dsold on the open marketNeurocrine Biosciences755 sharesup +78.0%up +85.1%
1 Jun 20185 Jun 2018SEC Form 44 dsold on the open marketNeurocrine Biosciences12,350 sharesup +58.6%up +56.9%
6 Feb 20187 Feb 2018SEC Form 41 dhad shares withheld for taxnot a tradeNeurocrine Biosciences917 sharesup +89.4%up +88.8%
5 Feb 20187 Feb 2018SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative34,750 sharesup +91.7%up +88.8%
5 Feb 20187 Feb 2018SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative6,150 sharesup +91.7%up +88.8%
5 Feb 20187 Feb 2018SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative12,250 sharesup +91.7%up +88.8%
5 Feb 20187 Feb 2018SEC Form 42 dsold on the open marketNeurocrine Biosciences820 sharesup +91.7%up +88.8%
7 Feb 20178 Feb 2017SEC Form 41 dsold on the open marketNeurocrine Biosciences132 sharesup +258.3%up +256.3%
6 Feb 20178 Feb 2017SEC Form 42 dsold on the open marketNeurocrine Biosciences821 sharesup +261.3%up +256.3%
6 Feb 20178 Feb 2017SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative76,800 sharesup +261.3%up +256.3%
6 Feb 20178 Feb 2017SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative10,600 sharesup +261.3%up +256.3%
5 Feb 20169 Feb 2016SEC Form 44 dwas grantednot a tradeNeurocrine Biosciencesderivative8,700 sharesup +334.1%up +385.3%
5 Feb 20169 Feb 2016SEC Form 44 dwas grantednot a tradeNeurocrine Biosciencesderivative41,200 sharesup +334.1%up +385.3%
5 Feb 20169 Feb 2016SEC Form 44 dwas grantednot a tradeNeurocrine Biosciencesderivative20,500 sharesup +334.1%up +385.3%
1 Jun 20153 Jun 2015SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative60,000 sharesup +273.9%up +259.4%
1 Jun 20153 Jun 2015SEC Form 42 dwas grantednot a tradeNeurocrine Biosciencesderivative25,000 sharesup +273.9%up +259.4%

Both percentages are the stock’s move, not Eric Benevich’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 11 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 172 of the 172 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.